- Dong Hoon SHIN, Ph.D.(adjunct professor)
- Faculty Appointment
- Associate Professor, Department of Cancer Biomedical Science, NCC-GCSP
Associate Scientist, Lung Cancer Branch
Research Institute, National Cancer Center
- Highest Academic Qualification
- Ph.D., Department of Pharmacology, College of Medicine, Seoul
National University, Seoul, Republic of Korea.
- Area of Expertise
- Work Experience
- 05/2009 – 06/2011., Thoracic head and neck Medical Oncology, M.D. Anderson Cancer
Center, Houston, USA.
07/2011 – 02/2014, Research professor, Department of Pharmacology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Educational Background
- 02/2004 B.S., Life science, College of Natural science,
Ajou University, Su-won, Gyeonggi-do, Republic of Korea.
02/2006 M.A., Department of Pharmaceutical, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
02/2009 Ph.D., Department of Pharmacology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Research Interests (Please place in paragraph form)
- Research Themes
The main research interest in my laboratory is the study of anti-cancer drug resistance in lung cancer. Chemoresistance has two type’s resistances such as innate resistance and acquired resistance. Innate resistance is a hallmark of cancer. In recent years, acquired resistance has emerged as a serious challenge to targeted cancer therapy, which abolished the efficacy of successful targeting drugs. Cancer cells gain the resistance property through a variety of mechanisms, involving cellular intrinsic and extrinsic factors. The study of these kinds of resistance factors will lead to implementation of more effective treatment regimens, and also the design of new approaches to preventing the emergence of resistance.
Current Research Projects
1. The mammalian stress response gene sirtuin 1, SIRT1 plays a critical role in multiple aspects and give effects several key molecules of lung cancer drug resistance. Especially, we are doing search the role of SIRT1 in lung cancer driver mutations.
2. Growing tumors make hypoxia more and more. Conversely, this hypoxia makes result in more resistance cancer cells. In this point, we are interesting the role of stromal cells exposed by hypoxia of tumor microenvironment induced by cancer cells.
3. Several lung cancer driver mutations such as EGFR, KRAS, ALK and so on are identified. But, around 40% unknown factors still make lung cancer patient. Now, we are doing research finding new lung cancer driver mutation and identifying the function of new driver mutation.
- International Collaboration
- American Association for Cancer Research (AACR)
Member 11/2009 – Present
American Head and Neck Society (AHNS)
Member 08/2010 – Present
2022 SCI-E Early On- treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: CANCERS. 14(6):1512~ (6.575)
2021 SCI-E Rapid androgen-responsive proteome is involved in prostate cancer progression: BIOMEDICINES. 9(12):1877~ (6.081)
2021 SCI-E Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1: ONCOGENE. 41(2):280~292 (9.867)
2021 SCI-E Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses: CELLULAR & MOLECULAR IMMUNOLOGY. Online:Published (8.484)
2021 SCI-E PGC1alpha Loss Promotes Lung Cancer Metastasis through Epithelial-Mesenchymal Transition: CANCERS. 13(8):1772~ (6.639)
2021 SCI-E Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model: INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES. 17(3):689~701 (6.582)
2020 SCI-E Midkine is a potential therapeutic target of tumorigeneiss, angiogenesis, and metastasis in non-small cell lung cancer: CANCERS. 12(9):2402~ (6.126)
2020 SCI-E Identification of MYC as an anti-necroptotic protein that stifles RIPK1-RIPK3 complex formation: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 117(33):19982~19993 (9.412)
2019 SCI QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth: INTERNATIONAL JOURNAL OF CANCER. 145(6):1585~1595 (4.982)
2019 SCI-E HSF1 regulates mevalonate and cholesterol biosynthesis pathways: CANCERS. 11(9):E1363~E1363 (6.162)
2018 SCI Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness: Experimental & molecular medicine. 50(1):137~137 (5.584)
2018 SCI Inhibition of Estrogen signaling reduces the incidence of BRCA1-associated mammary tumor formation: INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES. 14(12):1755~1768 (4.057)
2018 SCI Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors: International journal of biological sciences. 14(13):1769~1781 (4.057)
2018 SCI EGFR and HER3 signaling blockade in invasive mucinous lung adnocarcinoma harboring an NRG1 fusion: Lung cancer. 124:71~75 (4.486)
2018 SCI-E Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 19(1):1~1 (3.687)
2018 SCI-E Dual targeting of ERBB2/ERBB3 for treatment of SLC3A2-NRG1-mediated lung cancer: Molecular cancer therapeutics. 17(9):2024~2033 (5.365)
2017 SCI Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCap prostate cancer cells: Experimental Cell Research. 359(1):215~225 (3.546)
2016 SCI Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity.: Experimental and Molecular Medicine. 48(12):e277~e277 (5.164)
2016 SCI-E Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung: Oncotarget. 7(43):69450~69465 (5.008)
2016 SCI-E The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation: Oncotarget. 7(28):43315~43323 (5.008)
2016 SCI-E Distinct effects of SIRT1 in cancer and stromal cells on tumor promotion: Oncotarget. 7:23975~23987 (5.008)
2016 SCI The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL: Scientific Reports. Online:Published (5.578)
2014 SCI NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2.: Nature communications. 5:5176~5176 (10.742)
2014 SCI Plant homeodomain finger protein 2 promotes bone formation by demethylating and activating Runx2 for osteoblast differentiation1: Cell Research. 24(10):1231~1249 (11.981)
2014 SCI Differential roles of SIRT1 in HIF-1α and HIF-2α mediated hypoxic response: Biochemical and biophysical research communications. 444(1):36~43 (2.281)
2014 SCI SIRT1and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin: Cancer Res. 74:298~308 (8.65)
2013 SCI Combating resistance to anti-IGFR antibody by targeting the integrin beta？3-Src pathway: J Natl Cancer Inst. 105(20):1558~1570 (14.336)
2011 SCI Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer: Cancer Res. 71:7670~7682 (8.438)
2011 SCI-E Akt/mammalian target of rapamycin counteract the antitumor activities of cixtumumab an anti-insulin-like growth factor I receptor monoclonal antibody: Mol Cancer Ther. 10:2437~2448 (5.596)
2009 SCI-E Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase: PLoS One. 14:e7541~e7549 (4.35)
2009 SCI Inhibitor of nuclear factor-kappaB alpha derepresses hypoxia-inducible factor-1 during moderate hypoxia by sequestering factor inhibiting hypoxia-inducible factor from hypoxia-inducible factor 1alpha: FEBS J. 276:3470~3480 (3.421)
2008 SCI-E A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1？: Mol Cancer Ther. 7:3729~3738 (5.449)
2008 SCI Oxygen-dependent effect of bortezomib on FIH-mediated repression of HIF-1: Blood. 111:5259~5261 (10.896)
2008 SCI CITED2 mediates the paradoxical responses of HIF-1 alpha to proteasome inhibition: Oncogene. 27:1939~1944 (6.582)
2008 SCI Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1: Blood. 111:3131~3136 (10.896)
2007 SCI Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: Cancer Lett. 255:107~116 (3.277)
2006 SCI Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms: Journal of Neurochemistry. 96:561~572 (5.2)